Shots:

• The P-III QuANTUM-First trial evaluates quizartinib vs placebo in combination with standard induction and consolidation CT & continued with quizartinib as monothx. in a ratio (1:1) in 539 patients aged 18-75yrs. with newly diagnosed FLT3-ITD positive AML at ~ 200 study sites globally including in Asia, EU, America & Oceania
• The results showed an improvement in OS over standard treatment alone. The safety of quizartinib was manageable & consistent with the known safety profile. The results will be shared with authorities globally
• Quizartinib is an oral, highly potent & selective type II FLT3 inhibitor & is approved for use in Japan under the brand name Vanflyta to treat r/r FLT3-ITD AM

  | Ref: Daiichi Sankyo | Image: Daiichi Sankyo